Scarica l'app Stockscreener
19.02
1.30%
-0.25
Dopo l'orario di chiusura:
19.02
Precedente Chiudi:
$19.27
Aprire:
$18.96
Volume 24 ore:
701.05K
Relative Volume:
5.43
Capitalizzazione di mercato:
$483.39M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
+1.79%
1M Prestazione:
+12.28%
6M Prestazione:
-16.91%
1 anno Prestazione:
-6.30%
Intervallo 1D:
$18.73
$19.88
Intervallo di 1 settimana:
$16.70
$20.05
Portata 52W:
$11.66
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
19.02 | 483.39M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG Research Begins Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
BTIG initiates Buy rating on Cartesian Therapeutics stock highlighting mRNA CAR-T potential - Investing.com
Cartesian Therapeutics Announces New Employment Inducement Grants - Barchart
Cartesian Therapeutics Awards Key Talent with mRNA Cell Therapy Stock Options in Strategic Growth Move - StockTitan
Fmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Fmr LLC Has $45.97 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Produces Durable Responses in Myasthenia Gravis - CGTLive™
Cartesian Therapeutics (NASDAQ:RNAC) Earns “Buy” Rating from Needham & Company LLC - Defense World
Analysts Issue Forecasts for RNAC FY2024 Earnings - MarketBeat
Moving into Phase III, Cartesian data show momentum - The Pharma Letter
Cartesian Therapeutics Reports Promising Phase 2b Trial Results - Yahoo Finance
Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Cartesian Therapeutics Announces Positive Updated Results - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis Treatment - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.33 Consensus Price Target from Brokerages - Defense World
Great Point Partners LLC Invests $3.22 Million in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.33 - MarketBeat
Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Cartesian therapeutics CTO sells $649,029 in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics CTO sells $649,029 in stock - Investing.com India
Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - The Manila Times
Cartesian Therapeutics to Present Key Phase 2b Trial Data for Myasthenia Gravis Treatment | RNAC Stock News - StockTitan
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million By Investing.com - Investing.com Nigeria
Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com
Cartesian Therapeutics executive sells $875,042 in stock - Investing.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance
Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN
HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat
Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan
Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cartesian Therapeutics Inc Azioni (RNAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kurtoglu Metin | Chief Technology Officer |
Dec 10 '24 |
Option Exercise |
1.41 |
2,901 |
4,090 |
53,934 |
| Kurtoglu Metin | Chief Technology Officer |
Dec 09 '24 |
Sale |
25.50 |
10,763 |
274,494 |
51,033 |
| Kurtoglu Metin | Chief Technology Officer |
Dec 10 '24 |
Sale |
24.35 |
2,901 |
70,640 |
51,033 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):